Effect of dyspnea and clinical variables on the quality of life and functional capacity in patients with chronic obstructive pulmonary disease and congestive heart failure

Ege University Medical Faculty Physical Medicine and Rehabilitation Department, Turkey.
Chinese medical journal (Impact Factor: 1.05). 04/2008; 121(7):592-6.
Source: PubMed


Chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) are two chronic diseases that affect negatively the functional condition and quality of life of patients. We assessed the effect of symptoms and clinical variables on the functional capacity and quality of life in COPD and CHF patients.
The study included 42 COPD and 39 CHF patients. In both patient groups, dyspnea was assessed using Borg scale; functional capacity by shuttle-walk and cardiopulmonary exercise test and quality of life by short form-36 (SF36).
No statistically significant difference was found in neither of the two disease groups regarding the dyspnea score, shuttle-walk test and the majority of subgroup scores of SF36 (P > 0.05). A statistically significant difference was observed in peak VO2 in favor of COPD group (P < 0.05). No significant relationship was established between dyspnea score and forced expiratory volume in one second (FEV1) in COPD patients, and left ventricular ejection fraction (LVEF) in CHF patients (P > 0.05). A significant negative correlation was observed between dyspnea score and functional capacity tests in both disease groups (P < 0.05). On the other hand, no relationship was found between LVEF and FEV1 and quality of life and functional capacity (P > 0.05).
It was revealed that symptoms have an impact on functional capacity and quality of life in both disease groups, however, objective indicators of disease severity do not show a similar relationship. Therefore, in addition to the objective data related to the disease, we recommend that symptoms should also be taken into consideration to assess cardiopulmonary rehabilitation program and during following-up.

Download full-text


Available from: Hale Karapolat, Feb 20, 2014
46 Reads
  • Source
    • "The differentiation between cardiac and pulmonary dyspnea is not easy without clinical evidence of these diseases [6]. A recent study showed that dyspnea-related symptoms have an impact on functional capacity and QOL in both diseases [7]. Thus, considered with the similarity in both diseases, it may be reasonable to apply a QOL questionnaire for respiratory failure to severe heart failure. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Major characteristics of symptomatic patients with heart failure are exercise intolerance, poor prognosis, and poor quality of life (QOL). However, most QOL questionnaires are applicable for patients with mild to moderate heart failure, and are not sufficiently sensitive to discriminate between patients with NYHA classes III and IV. Therefore, it is necessary to prepare a questionnaire focused on patients with severe heart failure. We developed a Japanese version of the Maugeri Foundation Respiratory Failure (MRF28) questionnaire and assessed validity and reliability of MRF28 in heart failure patients. The MRF28 questionnaire was evaluated in 124 patients with heart failure (NYHA classes: I, 24; II, 31; III, 52; IV, 17). Reliability was evaluated by internal consistency and test-retest reliability. Validity was determined by correlation with World Health Organization Quality of Life (WHOQOL) questionnaire and physiological parameters. The MRF28 showed high internal consistency and reproducibility. The total score and subscores were all increased with the progress of heart failure. The total score could differentiate patients among NYHA II, III, and IV, but could not between NYHA I and II. However, all subscores and total score changed consistently with changes in symptoms of heart failure. MRF28 is a valid and reliable disease-specific questionnaire for assessing QOL in symptomatic patients with heart failure. Thus, this questionnaire may be useful for a QOL evaluation of patients with moderate to severe heart failure.
    Journal of Cardiology 03/2009; 53(1):117-26. DOI:10.1016/j.jjcc.2008.09.011 · 2.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic obstructive pulmonary disease (COPD) is the major cause of morbidity and mortality throughout the world, charac- terized by progressive airflow limitation that is not fully reversible, and progressive disturb of the pulmonary function. The major cause of hospitalization in COPD patients is acute exacerbation and, despite optimal pharmacologic therapy, these patients often have symptoms that limit normal physical activities and impair their quality of life. Pulmonary rehabilitation improves exercise capacity, severity of dyspnea, health-related quality of live, fatigue, emotional function, depression and anxiety. For these reasons, the magnitude of benefit is generally superior to any other COPD therapy. The benefits of pul- monary rehabilitation also include improvement in functional exercise capacity, reductions in hospitalizations and improve- ments in cost-effectiveness.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: COPD is a preventable and treatable disease caused by exposure to tobacco smoke and poisonous gases. It is characterised by progressive obstruction of the airflow, irreversible once lesions occur in the parenchyma. This article aims to systematically review the disease and its treatment.DiscussionSmoking is the main cause of COPD and leads to decreased oxygenation via lung hyperinflation with reduced airflow as a systemic inflammatory process. This reduces resistance to fatigue of the skeletal musculature, leading to hypoxemia, decreased peripheral blood flow and also miscarriages and premature births. Inflammatory markers such as interleukins and TNF-alpha maintain the systemic picture. While smoking cessation improves hypoxemia and exercise intolerance, it does not repair damaged tissue. COPD is a serious disease which can be avoided by a wider understanding by the population of the harm smoking causes.
    Revista portuguesa de pneumologia 11/2009; 15(6):1157–1166. DOI:10.1016/S2173-5115(09)70172-1 · 1.17 Impact Factor
Show more